French Actos risk not seen with other diabetes drugs, and only in bladder cancer
This article was originally published in Scrip
Not long after the furore over its tardy withdrawal of Servier's antidiabetic Mediator, the French medicines regulator Afssaps has now said it will suspend Takeda's diabetes drugs Actos and Competact, both formulated with pioglitazone. The move follows results of a French study indicating an increased risk of bladder cancer but comes before the European Medicines Agency has concluded its own benefit:risk review of the drugs. The Japanese drug regulator had not taken any action over Actos by close of business on 10 June, but Germany's Federal Institute for Drugs and Medical Devices has announced that it has suspended the use of the drug.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.